Products for Research Use Only
RegisterLogin

Rofecoxib

CAT: 0804-HY-17372-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17372-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells) .
CAS Number
162011-90-7
Product Name Alternative
MK 966
UNSPSC
12352005
Hazard Statement
H302
Target
COX
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/Rofecoxib.html
Concentration
10mM
Purity
99.89
Solubility
DMSO : 33.33 mg/mL (ultrasonic)
Smiles
O=C1OCC(C2=CC=C(S(=O)(C)=O)C=C2)=C1C3=CC=CC=C3
Molecular Formula
C17H14O4S
Molecular Weight
314.36
Precautions
H302
References & Citations
[1]Rofecoxib, et al. Rofecoxib [Vioxx, MK-0966; 4- (4'-methylsulfonylphenyl) -3-phenyl-2- (5H) -furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290 (2) :551-60.|[2]Liu NN, et al. Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression. Clin Exp Ophthalmol. 2015 Jul;43 (5) :458-65.|[3]Stoppoloni D, et al. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer. 2010 Feb 2;9:27.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
COX-2

Alternative Products

CatalogName
B1454-100Rofecoxib

Popular Products